19 août 2022 – The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) started evaluating the application for a conditional marketing authorisation for Covid-19 vaccine Skycovion. Skycovion has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2. When a person is given the vaccine, their immune system is expected to identify the nanoparticles containing parts of the spike protein as foreign and produce natural defences - antibodies and T cells - against them.

For more information, see here.